21+
Age Verification
You must be 21 years of age or older to enter this site.
By entering, you confirm you are 21 years of age or older.
You must be 21 years of age or older to enter this site.
By entering, you confirm you are 21 years of age or older.
Sermorelin is a 29-amino acid truncated analogue of endogenous growth hormone releasing hormone (GHRH), corresponding to the first 29 residues of the native 44-amino acid GHRH peptide. Published research has demonstrated that this fragment retains the full receptor binding activity of the parent molecule, engaging the GHRH receptor (GHRH-R) with equivalent affinity in in-vitro binding assays.
As a selective GHRH receptor agonist, sermorelin has been extensively characterized in peer-reviewed literature for its pharmacological profile. The compound acts through the pituitary GHRH receptor, a G-protein coupled receptor that activates the cAMP/PKA signaling cascade. Multiple preclinical and clinical studies have evaluated sermorelin's receptor binding kinetics, selectivity profile, and pharmacokinetic parameters.
AXOM Sermorelin is manufactured under strict cGMP-equivalent protocols and verified to ≥99% purity via reverse-phase HPLC. Each lot is accompanied by a Certificate of Analysis documenting identity, purity, peptide content, and endotoxin levels. Available in 5mg lyophilized format for research use only.
Truncated GHRH fragment retaining full receptor binding activity — 29 amino acids corresponding to the biologically active N-terminal region of native GHRH.
Selective GHRH receptor agonist engaging the pituitary GHRH-R with high affinity, activating cAMP/PKA signaling pathways in published in-vitro studies.
≥99% HPLC-verified purity with full COA documentation. Every lot independently tested by third-party analytical laboratories.
Comprehensive review characterizing sermorelin's pharmacological profile as a GHRH(1-29) analogue. Details receptor binding characteristics, pharmacokinetic parameters, and the compound's selectivity for the pituitary GHRH receptor in controlled research settings.
Review of the GHRH-GHRH receptor axis with detailed analysis of sermorelin's mechanism of action at the molecular level. Characterizes the receptor binding domain, signal transduction cascade, and the structural basis for the retained activity of the (1-29) fragment.
Clinical pharmacokinetic study evaluating sermorelin's activity profile following subcutaneous administration in a controlled research protocol. Provides detailed data on absorption kinetics, peak activity windows, and receptor engagement characteristics.
| Product Name | Sermorelin (GHRH 1-29) |
| Synonyms | GRF(1-29)NH2, Geref, GHRH(1-29) |
| CAS Number | 86168-78-7 |
| Molecular Formula | C149H246N44O42S |
| Molecular Weight | ~3,357.88 Da |
| Sequence Length | 29 amino acids (GHRH fragment 1-29) |
| Receptor Target | GHRH Receptor (GHRH-R) |
| Purity | ≥99% (Reverse-Phase HPLC) |
| Form | Lyophilized white powder |
| Available Size | 5mg |
| SKU | LTF-SR-5 |
| Solubility | Soluble in sterile water, bacteriostatic water |
| Endotoxin | <1 EU/μg (LAL method) |
| Certification | COA included with every order |
| Intended Use | For research and laboratory use only |
Sermorelin is supplied as a lyophilized powder and should be reconstituted with sterile bacteriostatic water (BAC water) for research applications.
All orders ship within the continental United States via USPS or UPS. Peptides are shipped at ambient temperature — lyophilized peptides are stable during transit. Free shipping on orders over $250.
